12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sustiva efavirenz: Marketed

DuPont presented data from 1,200 patients in which the combination of Sustiva plus Glaxo Wellcome's Retrovir AZT and BioChem Pharma Inc.'s Epivir 3TC gave a significantly greater duration of response (longer...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >